The recent merger of Amersham Life Sciences and Pharmacia Upjohn's Pharmacia Biotech creates the biggest player in the research-based biotechnology industry, with combined pro forma sales of $700 million. Will the deal lead to a wave of consolidation in the industry, as suppliers try to keep up with fewer, bigger, and ever more biotech-driven big pharma customers?
Is the merger of the life sciences businesses of Amersham
International PLC and Pharmacia &
Upjohn Inc. 's the leading edge of a
consolidation age among research-based biotechnology suppliers?
In joining Amersham Life Sciencewith Pharmacia Biotech Ab to form Amersham Pharmacia Biotech Ltd. (APB) the pair have created the biggest company of its kind ($700mm in pro forma...
